The world’s best-selling biologic, AbbVie’s Humira (adalimumab), is now facing competition in Europe from at least four companies, although the US will have to wait until 2023 for competition.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,